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Abstract Abundant evidence suggests that indirect inhib-
itory modulation of glutamatergic transmission, via metab-
otropic glutamatergic receptors (mGluR), may induce
neuroprotection. The present study was designed to deter-
minewhethertheselectiveantagonistofmGluR1(3-ethyl-2-
methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)-methanone
methanesulfonate (EMQMCM), showed neuroprotection
against the kainate (KA)-induced excitotoxicity in vitro and
in vivo. In in vitro studies on mouse primary cortical and
hippocampal neuronal cultures, incubation with KA
(150 lM) induced strong degeneration [measured as lactate
dehydrogenase (LDH) efﬂux] and apoptosis (measured
as caspase-3 activity). EMQMCM (0.1–100 lM) added
30 min to 6 h after KA, signiﬁcantly attenuated the KA-
inducedLDHreleaseandpreventedtheincreaseincaspase-3
activity in the cultures. Those effects were dose- and time-
dependent. In in vivo studies KA (2.5 nmol/1 ll) was uni-
laterally injected into the rat dorsal CA1 hippocampal
region. Degeneration was calculated by counting surviving
neurons in the CA pyramidal layer using stereological
methods. It was found that EMQMCM (5–10 nmol/1 ll)
injectedintothedorsalhippocampus30 min,1 h,or3 h(the
higher dose only) after KA signiﬁcantly prevented the
KA-induced neuronal degeneration. In vivo microdialysis
studiesinrathippocampusshowedthatEMQMCM(100 lM)
signiﬁcantly increased c-aminobutyric acid (GABA) and
decreased glutamate release. When perfused simultaneously
with KA, EMQMCM substantially increased GABA release
and prevented the KA-induced glutamate release. The
obtained results indicate that the mGluR1 antagonist,
EMQMCM,mayexertneuroprotectionagainstexcitotoxicity
after delayedtreatment (30 minto 6 h). Theroleofenhanced
GABAergictransmissionintheneuroprotectionispostulated.
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Introduction
Glutamate is a major excitatory neurotransmitter in the
mammalian brain (Watkins and Evans 1981). It acts at
different receptor types: ionotropic (iGluRs) (NMDA,
AMPA, and kainate) and metabotropic (mGluRs). It is well
established that glutamatergic overactivation may lead to
neurodegeneration by the mechanism of excitotoxicity
(Olney 1978; Choi 1994; Olney and Ishimaru 1999). The
excitotoxic cell death has been observed in many brain
disorders, such as epilepsy, ischemia, stroke, or trauma
(Choi 1988, 1994).
Although experiments on animals have demonstrated
neuroprotective effects of the iGluR antagonists in the
central nervous system injury, however, they cause many
adverse effects, like ataxia, sedation, psychosis, and
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1998; Ikonomidou and Turski 2002), which makes them
useless in the clinic. Hence, an indirect inhibitory modu-
lation of the glutamatergic transmission seems to be more
promising neuroprotective strategy than the direct antago-
nism at iGluRs (Byrnes et al. 2009). Such indirect modu-
lation may be engendered by the compounds acting on
mGluRs. Metabotropic GluRs have been divided into three
groups, based on sequence homology and signal trans-
duction mechanisms (Pin and Duvoisin 1995). Group I
receptors are coupled to phospholipase C via Gq and their
activation leads to phosphoinositide hydrolysis and intra-
cellular mobilization of Ca
2? ions. Receptors of groups II
and III are coupled to Gi and negatively regulate adenylyl
cyclase activity but differ in their pharmacological prop-
erties (Conn and Pin 1997; Allen et al. 2000; Spooren et al.
2003).
Many evidences suggest that mGluRs may be a potential
targets for neuroprotective drugs (Nicoletti et al. 1996;
Bruno et al. 2001). Experimental studies have shown
neuroprotective effects after pharmacological activation of
group II and III mGluRs which decreased glutamatergic
transmission (Bruno et al. 1996, 1997; Gasparini et al.
1999). On the contrary, group I mGluR activation
enhanced glutamatergic excitation, and thus neuroprotec-
tion was observed after antagonists of these receptors
(Bruno et al. 1995; Rao et al. 2000; Flor et al. 2002). Group
I mGluRs include mGlu1 and mGlu5 receptors. The dis-
covery of selective mGluR agonists and antagonists opened
new perspectives for studying the role of individual
receptor subtypes and their importance as potential thera-
peutics (Spooren et al. 2003). The results indicated neu-
roprotective effect of mGluR5 antagonists in different
animal models (Bruno et al. 2000; Bao et al. 2001; Popoli
et al. 2004; Lea et al. 2005). Also our previous studies
demonstrated neuroprotective activity of the selective
mGluR5 antagonist, MTEP, against kainic acid (kainate)-
induced excitotoxicity. This effect was observed even after
delayed treatment, administered 3–6 h after the onset of
intoxication (Domin et al. 2006, 2010). Less is known
about mGluR1 ligands and the role of these receptors is
still controversial (Nicoletti et al. 1999; Allen et al. 2000).
Whereas the antagonists have shown neuroprotective
activity (Bruno et al. 1999; Faden et al. 2001; Cozzi et al.
2002), the agonists may induce both neurotoxicity or
neuroprotection in different experimental designs
(Copani et al. 1995; Nicoletti et al. 1999; Allen et al.
2000). Therefore, further studies on the neuroprotective
potential of compounds acting at mGlu1 receptors seem to
be very important. In the last years, a novel highly
selective uncompetitive mGlu1 receptor antagonist
(3-ethyl-2-methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)-meth-
anone methanesulfonate (EMQMCM) was synthesized
(Lesage et al. 2002) and its neuroprotective effects were
evidenced in some hypoxia–ischemia models (Makarewicz
et al. 2006; Szydlowska et al. 2007). Moreover, the com-
pound was also active in some behavioral experiments, in
anxiety, depression, or learning tests (Gravius et al. 2005;
Pietraszek et al. 2005; Belozertseva et al. 2007; Kotlinska
and Bochenski 2008).
Therefore, in this study, we examined whether
EMQMCM can exert a protective action against excito-
toxicity induced by kainic acid (KA), with special focus
on the efﬁcacy of delayed treatment. The model of
KA-induced neurodegeneration was chosen, as a good and
validated simulation of various pathological effects of toxic
glutamatergic overactivation occurring, e.g., in epilepsy,
ischemia, and traumatic injuries (Coyle 1983; Ferkany and
Coyle 1983; Wang et al. 2005), because kainic acid acts not
only directly by postsynaptic KA receptor stimulation but
also by a secondary massive release of endogenous gluta-
mate which activates all Glu receptors and leads to neu-
rodegeneration (McGeer et al. 1978; Ferkany et al. 1982;
Ferkany and Coyle 1983). Therefore, the KA intoxication
seems to induce wider effects than a speciﬁc stimulation of
NMDA receptors and thus it more resembles clinical sit-
uations. Moreover, the KA-induced neurodegeneration
develops slowly which makes it useful for studying delayed
neuroprotection (Mazzone et al. 2010; Mazzone and Nistri
2011). For the in vivo studies, KA microinjection into the
CA1 hippocampal region was chosen on the basis of our
previous studies (S ´miałowska et al. 2003) as this dose and
mode of treatment did not induce generalized seizures
(some clonic movements of forepaws and mouth were only
observed), and the extent of degeneration was limited. The
degenerations were evaluated by determination of cell
death both in vitro (LDH release) and in vivo (stereological
counting of neurons).
While studying the mechanism of neuroprotective
effects of EMQMCM, we focused on two problems (1) a
possibility of its antiapoptotic effects and (2) its inﬂuence
on glutamate and c-aminobutyric acid (GABA) release. In
the ﬁrst series of experiments, we decided to estimate
caspase-3 activation, as it is known that KA induces a
strong caspase-3 activation (Liu et al. 2001; Wang et al.
2005; Domin et al. 2006) and our previous and other
studies have shown that mGluR I antagonists attenuated
this effect. For caspase-3 estimation, we chose an in vitro
model because it gave us a possibility of quantitative
analysis and studying different doses and time of treatment
in one set of experiments. In the second experimental series
concerning the mechanism of EMQMCM protective
action, the evaluation of GABA and glutamate release in
the hippocampus by means of a microdialysis method in
freely moving rats was chosen, since some authors sug-
gested that mGluR1 antagonists increased GABA release
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(Pellegrini-Giampietro et al. 1999; de Novellis et al. 2003;
Musante et al. 2008).
Materials and Methods
In Vitro Studies: Cortical and Hippocampal Primary
Neuronal Cultures
Materials
The experiments were performed on primary cultures of
mouse cortical and hippocampal neurons. Neuronal tissues
were taken from Swiss mouse embryos on days 15/16 (for
cortical cultures) and 17/18 (for hippocampal cultures) of
gestation, and were cultivated essentially as described
previously (Brewer 1995; Kajta et al. 2004). Pregnant
females were anesthetized with CO2 vapor, killed by cer-
vical dislocation, and subjected to cesarean section to
remove fetal brains. The dissected cortical and hippocam-
pal tissues were minced, then gently digested with trypsin
[0.1%; for 15 min at room temperature (RT); Sigma,
USA], triturated in the presence of 10% fetal calf serum
(Gibco, USA) and DNAse I (170 Kunitz units per ml,
Sigma, USA), and ﬁnally centrifuged for 5 min at
1,0009g. The cells were then suspended in phenol red-free
Neurobasal medium (Gibco, USA) supplemented with 5%
fetal calf serum and plated at a density of 1.5 9 10
5 cells
per cm
2 onto poly-ornithine (0.01 mg per ml; Sigma,
USA)-coated multi-well plates (TPP). After 2 days, the
culture medium was exchanged to neurobasal medium
supplemented with B27 (200 ll/100 ml; Gibco, USA).
This procedure typically yields cultures that contain about
90% of neurons and 10% of astrocytes. The cultures were
maintained at 37C in a humidiﬁed atmosphere containing
5% CO2 and were cultivated for 8 days prior to the
experiment.
Treatment with Drugs
In order to evoke toxic effects, primary neuronal cultures
were exposed to 150 lM kainic acid (KA; Tocris, USA),
dissolved in redistilled water, for 24 h (hippocampal cul-
tures) or 48 h (cortical cultures). The concentration of KA
used in our experiments was chosen on the basis of our
earlier studies (Kajta et al. 1999; Kajta and Lason ´ 2000;
Domin et al. 2006) and also other authors research (Shih
et al. 2002, 2004). The time-course of kainate effects on
caspase-3 activity and LDH release on primary neuronal
cultures was worked out and described in our earlier paper
(Domin et al. 2006). Selective mGluR1 antagonist (3-ethyl-
2-methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)-methanone
methanesulfonate [EMQMCM (originally JNJ 16567983,
JNJ, Belgium) is a gift, synthesized by Merz Pharmaceu-
ticals, Frankfurt am Main, Germany] at concentrations of
0.1, 1, 10, and 100 lM was applied 30 min, 1 h, 3 h, or
6 h, after starting the exposure to KA. EMQMCM con-
centrations were chosen on the basis of our pilot experi-
ments and a study by Szydlowska et al. (2007). EMQMCM
was dissolved in redistilled water. The control cultures
were supplemented with the same amount of an appropriate
vehicle.
Evaluation of Cell Death and Protection
Measurement of Lactate Dehydrogenase (LDH) Activity
In order to quantify cell death, LDH released from dam-
aged cells into the cell culture media was measured 24 h
(hippocampal cultures) and 48 h (cortical cultures) after
starting the treatment with kainate. A colorimetric assay
was used, according to which the amount of formazan salt,
formed after conversion of lactate to pyruvate and then by
reduction of tetrazolium salt, was proportional to LDH
activity in the sample. Cell-free culture supernatants were
collected from each well and incubated with the appro-
priate reagent mixture according to the supplier’s instruc-
tions (Cytotoxicity Detection Kit, Roche) at RT for 20 min.
The intensity of red color formed in the assay and mea-
sured at a wavelength of 490 nm was proportional to LDH
activity and to the number of damaged cells. The data were
normalized to the activity of LDH released from vehicle-
treated cells (100%) and expressed as a percent of the
control ± SEM established from n C 6 wells per one
experiment from three separate experiments. Absorbance
of blanks, determined as no-enzyme control, has been
subtracted from each value.
Measurement of Caspase-3 Activity
For evaluation of apoptosis, caspase-3 activation was
measured. The method was performed according to Nich-
olson et al. (1995) and Kajta et al. (2005, 2007) in samples
treated for 6 h with the neurotoxic agent KA, alone or in
combination with EMQMCM applied 30 min after KA.
After replacing the media with Caspase Assay Buffer
(50 mM HEPES, pH 7.4, 100 mM NaCl, 0.1% CHAPS,
1 mM EDTA, 10% glycerol, and 10 mM dithiothreitol),
the cell lysates (25 lg per sample) were incubated at 37C
with a colorimetric substrate preferentially cleaved
by caspase-3-Ac-DEVD-pNA (N-acetyl-asp-glu-val-asp
p-nitro-anilide; 40 lM; Sigma, USA). The amounts of
p-nitro-anilide were continuously monitored over 60 min
with a plate reader (Multiscan, Labsystems). Absorption
was measured at 405 nm and only the data within the linear
Neurotox Res (2012) 21:379–392 381
123slope of the reaction curve provided consistent measure of
caspase-3 activity. To conﬁrm the correlation between
signal detection and caspase activity, we used Ac-DEVD-
CHO (aldehyde substrate; Molecular Probes, USA), which
is a speciﬁc caspase-3 protease inhibitor. The data were
normalized to the absorbance in vehicle-treated cells and
expressed as a percent of control ± SEM established from
n C 6 wells per one experiment from two separate exper-
iments. Absorbance of blanks, determined as no-enzyme
control, has been subtracted from each value.
Identiﬁcation of Apoptotic Cells
Apoptotic cells were visualized by ﬂuorescent staining
using Hoechst 33342 (Molecular Probes, USA) according
to Kajta et al. (2007) and S ´miałowska et al. (2009). Cells
for those studies were cultured, as described above, on
round cover-glasses (Menzel-Glasser, Germany), placed in
24-holes culture plates. The cultures were treated with KA
alone, or with KA and the EMQMCM. At 24 h (hippo-
campal cultures) or 48 h (cortical ones) after the start of
incubation with KA (or without KA in control groups), the
cultures were washed with phosphate buffer saline (PBS),
ﬁxed for 20 min with 4% paraformaldehyde, washed sev-
eral times in PBS, and then exposed to Hoechst 33342
(0.6 lg/ml in PBS) for 10 min at RT. Hoechst 33342 stains
condensed DNA fragments characteristic for apoptotic
cells. Bright-blue ﬂuorescence of the condensed chromatin
was observed under a ﬂuorescence microscope (Nicon
Optiphot 2) using a wave length of 330–380 nm. Micro-
photographs were made using SPOT 32 camera (Diag-
nostic Instruments, Inc.).
Data Analysis
The data after normalization as a percentage of con-
trol ± SEM were analyzed using GraphPad Prism 4.0
software. One-way analysis of variance (ANOVA) was
used to determine overall signiﬁcance. Differences
between control and experimental groups were assessed




Male Wistar rats weighing about 250–300 g were used for
the experiments. The rats were age-matched and were
housed six to a cage on a 12:12 light–dark cycle, with free
access to food and tap water. The rats after cannulae
implantation were housed singly. During the experiment,
all efforts were made to minimize animal suffering and to
reduce the number of animals used, in accordance with the
Local Bioethical Commission Guide for the Care and Use
of Laboratory Animals.
Cannulae Implantation
The rats were anaesthetized with equithesin and were ste-
reotaxically, bilaterally implanted with chronic guide can-
nulae aimed at the dorsal hippocampus CA1 region. The
guide cannulae (23-gauge stainless steel tubing), secured
by dental cement, were anchored to the skull by three
stainless steel screws. In order to prevent clogging, stain-
less steel stylets were placed in the guide cannulae and left
until the animals were microinjected.
Drug Treatments
Seven days after cannulae implantation, the rats were
unilaterally microinjected with KA (Tocris, USA) into
the dorsal hippocampus CA1 region (coordinates: A =
?5.7 mm, L =± 2.1 mm, H =? 7.2 mm from the inter-
aural line, according to the Paxinos and Watson (1986)
stereotaxic atlas. KA was freshly dissolved in 0.1 M
phosphate buffer, pH 7.4 and was microinjected unilater-
ally in a dose of 2.5 nmol/1 ll. Some rats were addition-
ally injected, through the same cannulae with mGluR1
antagonist EMQMCM. EMQMCM was dissolved in
redistilled water, and was injected in doses of 1, 5, or
10 nmol/1 ll into the CA1 region, 30 min, 1 h, 3 h, or 6 h
after KA. The contralateral hippocampus of each rat was
microinjected with a phosphate buffer and redistilled water,
respectively, and used as a control side. The dose of KA was
chosen on the basis of our earlier study (S ´miałowska et al.
2003). The doses of EMQMCM and time schedule of
treatment were chosen on the basis of Domin et al. (2010)
which authors showed neuroprotective effects of another
group I mGlu receptor, such as mGlu5 antagonist MTEP.
Evaluation of Damage and Protection in CA Region
of Hippocampus
Tissue Preparation and Histology
Seven days after treatment, the rats were killed by an
overdose of pentobarbital, their brains were removed, ﬁxed
in cold, buffered 4% paraformaldehyde for 7 days, and
were then immersed in a buffered 20% sucrose solution for
at least 5 days at 4C. The brains were then frozen on dry
ice, and 30-lm coronal sections were cut at levels con-
taining the dorsal hippocampus (between bregma -2.12
and -4.30 mm, according to the Paxinos and Watson
(1986) atlas. The sections were mounted on glass slides,
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Permount, and were used for veriﬁcation of the injection
site and for a histological analysis of the lesion.
Stereology
The total number of neurons in the pyramidal layer of the
CA of the dorsal hippocampus was evaluated by stereolo-
gical counting. The procedures were performed using a
microscope (Leica, DMLB; Leica, Denmark) equipped
with a projecting camera and a microscope stage connected
to an xyz stepper (PRIOR ProScan) controlled by a
computer using the Olympus Denmark CAST2 software, as
described previously (Ossowska et al. 2005, 2006;
S ´miałowska et al. 2009).
Systemic uniform random sampling was used to choose
the sections. The ﬁrst sampling item was randomly taken
from the frontal part of the dorsal hippocampus, and all the
following sampling items were taken at a ﬁxed distance
from the previous one. At least 10–12 sections through the
entire length of the dorsal hippocampus were sampled.
The total number of cells (N) in the pyramidal layer of
the hippocampal CA region was estimated by measuring
the reference volume (Vref, the area that contains the pop-
ulation of the cells) and the numerical density (Nv) of the
cells within the Vref:
N ¼ Vref   Nv
The pyramidal layer of the dorsal hippocampus CA
region was outlined at a lower magniﬁcation (59). CAST2
software provides templates of points in various arrays
used in point counting for reference volume estimation.
The Vref value was determined using point counting
methods and applying Cavalieri’s principle (Gundersen
and Jensen 1987) according to the formula:
Vref ¼
X
pi   A pi ðÞ   t
where
P
pi is the sum of the number of points (pi) counted,
A(pi) is the area associated with each point, and t is the
known distance between sections. The area of the counting
frame was A(fr) = 3382 lm
2.
For determination of the density of cells in the hippo-
campal CA region, the computer software generated a
random selection of sites within the outlined area, from
which the density was determined under higher magniﬁ-
cation (639). Cell density (Nv) was estimated using the





P   vðdisÞ
where
P
Q is the sum of cells counted from all the dis-
sector frames,
P
P is the total number of all the dissector
points, and v(dis) is the total volume of the dissector.
Data Analysis
Statistical analysis was carried out using GraphPad Prism
4.00 software. Differences between the control (contralat-
eral) and the KA-lesioned hippokampi (ipsilateral) were
compared by a paired two-tailed t test. Differences between
KA-lesioned and KA ? EMQMCM-treated hippocampi
were compared by an unpaired two-tailed t test. P value
less than 0.05 was considered statistically signiﬁcant.
In Vivo Microdialysis Studies
The rats were anesthetized with ketamine (75 mg/kg i.m.)
and xylazine (10 mg/kg i.m.) and placed in a stereotaxic
apparatus (David Kopf Instruments, Tujunga, CA, USA).
The skull was exposed and small holes were drilled for the
insertion of the vertical microdialysis probes in the dorsal
hippocampus using the following coordinates: AP =
-3.3 mm anterior from the bregma; L =? 2.2 mm lateral
from the sagittal suture; and H =- 4.0 mm ventral from
the dura surface according to the Paxinos and Watson
(1986) stereotaxic atlas. Microdialysis probes were con-
structed as described in detail elsewhere (Gołembiowska
and Dziubina 2004a, b). One day after the surgery and
probe implantation, the inlet of the dialysis probes was
connected to a syringe pump (BAS, IN, USA) which
delivered an artiﬁcial cerebrospinal ﬂuid (aCSF) composed
of [in mM]: NaCl 147, KCl 4, CaCl2 2.2; pH 7.4 at a ﬂow
rate of 1.5 ll/min. After 3 h of washing period, when the
extracellular level of neurotransmitters became stable, four
baseline samples were collected every 30 min. Next,
freshly prepared solutions of KA (50 lM) in aCSF was
perfused locally through a microdialysis probe for 30 min.
EMQMCM (100 lM) or KA ? EMQMCM in aCSF
(EMQMCM was administered simultaneously with kai-
nate) were perfused locally through a microdialysis probe
for 30 min. Then the perfusion ﬂuids were switched back
to aCSF or EMQMCM for three additional collection
periods. The concentration of EMQMCM was chosen on
the basis of our in vitro experiments, presented here, as
very effective even after 6 h delay. At the end of the
experiment the rats were killed and their brains were
examined histologically to validate the correct probe
placement.
Analytical Procedure
Glutamate was measured in dialysates (20 ll) after deriv-
atization with 4-dimethylaminoazobenzene-40-sulfonyl-
chloride (DABS-Cl) at 70C for 12 min, according to
Knecht and Chang (1986). Dabsylated amino acids were
separated on an Ultrasphere ODS (4.6 9 150 mm, 3 lm)
column (Supelco, Poznan ´, Poland) by gradient elution,
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ide) and solvent B (acetonitrile). Dabsylated compounds
were detected by measuring an absorbance at 436 nm using
Beckman Amino Acid System Gold with VIS detection.
GABA in extracellular ﬂuid was measured electro-
chemically after derivatization with OPA/sulﬁte reagent to
form isoindole-sulfonate GABA-derivative. OPA/sulﬁte
reagent was prepared by dissolving 22 mg o-phthaldial-
dehyde (OPA) in 0.5 ml of absolute ethanol. A 0.5 ml
volume of 1 M sodium sulﬁte was added followed by 9 ml
of 0.1 M sodium tetraborate adjusted to pH 10.4 with
sodium hydroxide. The working OPA/sulﬁte solution was
prepared by diluting 50 ll of OPA/sulﬁte stock solution
with 5 ml of water. Precolumn GABA derivatization was
performed by mixing 10 ll of the working OPA/sulﬁte
with 10 ll of microdialysate for 10 min at RT before
analysis. Chromatography was performed using an LC-10
AD pump (Shimadzu Europa GmbH, Warsaw, Poland), an
LC-4B aperometric detector with a cross-ﬂow detector cell
(BAS, IN, USA), and a HR-80 column (80 9 4.6 mm,
3 lm; ESA Inc., USA). The mobile phase consisted of
100 mM monosodium orthophosphate, 25% methanol, pH
4.6. The ﬂow rate was 0.9 ml/min, and the applied poten-
tial of a 3-mm glassy carbon electrode was ?600 mV at a
sensitivity of 5 nA/V. GABA-derivative peak was com-
pared with respective standard and was processed by
Chromax 2005 (Pol-Lab, Warsaw, Poland) software on a
personal computer. The obtained values were not corrected
for in vitro probe recovery, which was approximately 10%.
Statistical Analysis
The statistical signiﬁcance of microdialysis data was cal-
culated using one-way ANOVA for repeated measures,
followed by Tukey’s post hoc test. The results were con-
sidered statistically signiﬁcant when P\0.05.
Results
Effect of EMQMCM in Primary Cultures
Application of EMQMCM, the selective mGlu1 antagonist,
signiﬁcantly decreased the KA-induced LDH release in
both cortical (Fig. 1a) and hippocampal (Fig. 1c) cultures.
The effect was dose- and time-dependent. When
EMQMCM was added 30 min or 1 h after KA, at con-
centrations of 0.1, 1, 10, and 100 lM, signiﬁcant diminu-
tion of LDH release (about 20–35%) in cortical and (about
17–54%) in hippocampal cultures was found. Signiﬁcant
inhibition was also observed when EMQMCM at concen-
trations of 10 and 100 lM (but not 0.1 and 1 lM) was
applied 3 h after KA: by 27% in cortical cultures and by
32% in hippocampal ones (Fig. 1a, c). Protective
effects also appeared when EMQMCM was applied 6 h
after KA, but only at concentrations 100 lM (about 23%
decrease in cortical and about 33% decrease in hippo-
campal ones) (Fig. 1a, c). EMQMCM alone, applied into
untreated cultures, did not inﬂuence LDH activity at any
dose studied. The measurement of caspase-3 activity
showed potent activation of that apoptotic enzyme after 6 h
of KA intoxication, reaching ca. 170% of the control
value. Application of EMQMCM 30 min after KA, at
concentrations of 0.1, 1, 10, and 100 lM prevented the
KA-induced increase in caspase-3 activity in both cortical
and hippocampal cultures (Fig. 1b, d). The level of cas-
pase-3 activity after EMQMCM at concentrations of 10
and 100 lM reached the control value. EMQMCM alone
added to the cultures, did not inﬂuence caspase-3 activity.
Morphological Identiﬁcation of Apoptotic Cells
by Hoechst 33342 Staining
Kainate applicated into the cultures at a concentration of
150 lM induced the appearance of apoptotic bodies after
24 h in hippocampal cultures, or 48 h in cortical ones.
The apoptotic bodies were visibly less numerous when
EMQMCM was added into cultures 30 min after KA.
Figure 2presentstheresultsobtainedinhippocampalcultures.
Effect of EMQMCM After Intrahippocampal Injection
in Vivo
Kainate injected unilaterally in a dose of 2.5 nmol into the
CA1 region of the dorsal hippocampus-induced extensive
neurodegeneration (50% loss) of CA pyramidal neurons
(Fig. 3a). Stereological counting showed a strong reduction
in the number of neurons in the pyramidal layer of the
ipsilateral dorsal hippocampus in comparison to the con-
tralateral side [t(6) = 12.38, P\0.0001, Fig. 4].
Cresyl violet staining showed that the extent of lesions in
the CA pyramidal layer was signiﬁcantly smaller in animals
treatedwithEMQMCM(Fig. 3c).TheeffectsofEMQMCM
were dose- and time-dependent. EMQMCM administered
30 min after KA at doses of 10 or 5 nmol/rat caused a sig-
niﬁcant increase in the number of visible neurons (an
increase by 63 and 42%, respectively, to dose) [t(12) =
4.744, P = 0.0005 and t(11) = 3.230, P = 0.0080, respec-
tively] in comparison with KA-lesioned hippocampi
(Fig. 4). EMQMCM used in dose of 1 nmol/rat did not
induce any signiﬁcant protection effect [t(9) = 0.8989,
P = 0.3921, Fig. 4].
NeuroprotectiveeffectwasalsoobservedwhenEMQMCM
at doses of 10 or 5 nmol was injected intrahippocampal 1 h
after KA. The results of stereological counting showed the
signiﬁcant increase in the number of living neurons in CA
384 Neurotox Res (2012) 21:379–392
123pyramidallayeroftheipsilateraldorsalhippocampus(increase
by 69 and 41%, respectively, to dose) [t(10) = 4.847,
P = 0.0007andt(11) = 2.605,P = 0.0245] compared to the
KA-lesioned hippocampi (Fig. 4).
A diminution of degeneration was also found when
EMQMCM was given 3 h after KA, but only at dose
10 nmol/rat (the number of living neurons signiﬁcantly
increased by 38% [t(10) = 2.620, P = 0.0256] in com-
parison to the side with KA alone) (Fig. 4).
MicroinjectionofEMQMCM6 hafterKAdidnotinduce
any protection [t(10) = 0.4322, P = 0.6748, Fig. 4].
Effect of EMQMCM on Extracellular Level
of Glutamate (GLU) and GABA Level in Rat
Hippocampus
EMQMCM given into rat hippocampus at concentration of
100 lM signiﬁcantly increased extracellular GABA level in
the hippocampal perfusate at 30–120 min after administra-
tion with the maximum level (356% of basal) after 60 min
[F(1,9) = 7.75, P = 0.021, Fig. 5b). Extracellular level of
GLU was decreased in comparison to control at 90 and
120 min after the treatment [F(1,9) = 8.13, P = 0.0019;
F(1,9) = 16.46, P = 0.0028, respectively] (Fig. 5a).
Kainic acid (KA) perfused locally into the hippocampus
at the concentration 50 lM for 30 min, induced a signiﬁ-
cant increase in extracellular GLU level in rat hippocampus
at 30, 60, 90, and 120 min after administration
[F(1,16) = 7.73, P = 0.013; F(1,16) = 10.1, P = 0.0058;
F(1,16) = 12.64, P = 0.0026; F(1,16) = 3.35, P = 0.05,
respectively] (Fig. 6a). Its effect on GABA extracellular
level was weaker since signiﬁcant increase was observed
only at 60 min after administration [F(1,14) = 5.52,
P = 0.038, Fig. 6b].
When EMQMCM at the concentration 100 lM was
perfused simultaneously with KA a very strong, signiﬁcant
Fig. 1 a, c The effect of EMQMCM on kainate (150 lM)-induced
LDH release in the primary cultures of mouse cortical (a) and
hippocampal (c) neurons. LDH was measured 48 h (cortical) or 24 h
(hippocampal cultures) after KA administration. EMQMCM (in
concentrations 0.1, 1, 10, and 100 lM) was added to the culture
medium 30 min, 1 h, 3 h, or 6 h after KA. b, d The effect of
EMQMCM on KA-induced increase in caspase-3 activity in mouse
primary cortical (b) and hippocampal cultures (d). Caspase-3 was
measured 6 h after starting KA intoxication. EMQMCM was added to
cultures 30 min after KA. Each bar represents the mean of n C 6
platings ± SEM from 3 to 4 independent experiments. Signiﬁcant
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123increase in GABA level was observed 30–120 min after
administration [F(1,13) = 26.22, P = 0.0002; F(1,13) =
5.84, P = 0.036; F(1,13) = 12.96, P = 0.004; F(1,13) =
16.28, P = 0.002, respectively] (Fig. 6b). The increase
was from 221% of baseline level after KA to about 471%
when EMQMCM was added. At the same time EMQMCM
prevented the KA-stimulated glutamate release [F(1,12) =
4.67, P = 0.05; F(1,12) = 6.68, P = 0.021; F(1,12) =
16.07, P = 0.001, respectively] (Fig. 6a).
Discussion
The obtained results indicate neuroprotective action of the
mGluR1 antagonist EMQMCM against KA-induced
excitotoxicity. Signiﬁcant effects were found both in vitro,
in the cortical and hippocampal neuronal cultures, and in
vivo after their intrahippocampal injection in the rat.
EMQMCM is a novel, highly selective uncompetitive
antagonist of mGlu1 receptors, easily penetrating the blood–
brain barrier (Lesage et al. 2002). Till now there have been
only a few studies on its neuroprotective potential. Szy-
dlowska et al. (2007) have shown a slight neuroprotective
action of EMQMCM in vitro in organotypic hippocampal
cultures exposed to the mitochondrial toxin 3-nitropropionic
acid and in vivo in the middle cerebral artery occlusion
model of stroke in rats. The EMQMCM-induced neuropro-
tection was also found in other ischemic models: 3-min
forebrain ischemia in gerbils and hypoxia–ischemia in
7-day-old rats (Makarewicz et al. 2006). These ﬁndings are
in line with our results showing the neuroprotective action
of EMQMCM in the model of kainate toxicity. More
studies were performed with other mGluR1 antagonists:
AIDA, CBPG, 3-MATIDA, CPCCOEt, LY367385, and
YM-202074, and their neuroprotective activity was docu-
mented (Bruno et al. 1999; Pellegrini-Giampietro et al.
1999; Faden et al. 2001; Cozzi et al. 2002; Kohara et al.
2008; Murotomi et al. 2008). Therefore, our present results
and all publications of other authors presented above have
indicated that antagonists of mGlu1 receptors seem to be
efﬁcient in protection against neuronal death in different
models of neuronal degeneration.
The question if neuroprotection observed in our present
study is speciﬁcally connected with a blockade of mGlu1
receptors is still open. Szydlowska et al. (2007) suggested
that EMQMCM at higher concentrations might interact
also with mGlu5 receptors or other targets, as they
observed neuroprotective effect at concentrations 300-fold
higher than those known to interact with mGlu1 receptors,
but their opinion was based on the data obtained in vitro
after 3-NP toxicity whereas we used cultures exposed to
KA-induced excitotoxicity, so the models were different.
Fig. 2 Selected microphotographs illustrating the ﬂuorescence stain-
ing with Hoechst 33342 (a marker of apoptosis) in hippocampal
cultures. Cell with bright fragmented nuclei (apoptotic bodies,
arrows) showing condensation of chromatin were identiﬁed as dying
in apoptotic mode. a A control culture with few apoptotic bodies. b A
culture after KA exposure (150 lM; 24 h); fewer healthy cells and
more apoptotic bodies can be seen. c A culture exposed to KA and
EMQMCM (100 lM; 30 min after KA); some neuroprotection can be
seen as a decrease in the number of apoptotic bodies in comparison
with KA (b)
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123On the other hand, concentrations used in our studies both
in vitro and in vivo are similar to those used in our previous
experiments with mGluR5 antagonist, MTEP (Domin et al.
2006, 2010) and the strong enhancement in GABA release,
found after EMQMCM in microdialysis studies, corre-
sponds well to the results obtained by other authors after
other mGluR1 antagonists which was postulated to be
characteristic of these compounds (Battaglia et al. 2001;
Cozzi et al. 2002). Therefore, all our results indicate that
the effects observed in this study are at least in majority
dependent on the interaction with mGluR1.
A new and important ﬁnding of our present study is the
observation that EMQMCM may be neuroprotective after
delayed application. In most of other studies, mGluR1
antagonists were given simultaneously or 30–120 min after
the onset of neurodegenerative treatment. EMQMCM was
found to be neuroprotective in the ischemic model when
given 2 h after the onset of ischemia (Szydlowska et al.
2007) or just immediately after hypoxia–ischemia
(Makarewicz et al. 2006). Also other mGluR1 antagonists
were given before, simultaneously or soon after the NMDA
excitotoxicity, ischemia, or trauma (Bruno et al. 1999;
Pellegrini-Giampietro et al. 1999; Rao et al. 2000; Faden
et al. 2001; Cozzi et al. 2002; Kohara et al. 2008;
Murotomi et al. 2008). In our present study, EMQMCM
was effective even if it was applied 6 h after the onset of
KA intoxication in the in vitro neuronal cultures, or after
3 h in the in vivo experiments with intrahippocampal
injection. The efﬁcacy of such delayed treatment seems to
be valuable and important.
The model of neurodegeneration used in our present
study was based on kainic acid-induced excitotoxicity. It
seems that the KA model may give better possibilities for
studying delayed neuroprotection than models based on
Fig. 3 Microphotographs of frontal sections of rat brain hippocampi
stained with cresyl violet. Pyramidal layer of CA regions is pointed by
arrows. Calibrations bars 200 lm. a Loss of neurons and extensive
gliosis is seen in CA after KA microinjection (2.5 lm/1 ll).
b Contralateral hippocampus is not degenerated. A small glial scar
only is seen in the site of the buffer injection. c Neuroprotective effect
of EMQMCM (10 nmol) injected into the hippocampus 3 h after KA.
The lesion is much smaller than after KA alone
Fig. 4 The effect of intrahippocampal injections of KA (2.5 nmol/
1 ll) and KA followed by EMQMCM on the number of neurons in
the pyramidal layer of CA regions. The results of stereological
counting showed neurodegeneration after KA (50% loss) and
neuroprotection induced by EMQMCM given 30 min, 1 h, or 3 h
after KA. No protection was seen when EMQMCM was given 6 h
after KA. Each bar represents the mean ± SEM of n = 6 per group.
***P\0.001 KA (ipsilateral) versus contralateral side;
#P\0.05,
##P\0.01,
###P\0.001 KA ? EMQMCM (ipsilateral) versus
KA-lesioned (ipsilateral) hippocampi
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123selective activation of ionotropic NMDA receptors. As
mentioned above in ‘‘Introduction,’’ the effect of KA
develops progressively, and endogenous glutamate gradu-
ally released from overexcited neurons enhances degener-
ation. Also in our earlier studies (Domin et al. 2006) with
the KA-excitotoxicity model, we demonstrated both grad-
ual increase in caspase-3 activity, with the maximum at 6 h
after the KA treatment and then LDH release with maxi-
mum 24–48 h after the KA administration. Moreover, the
KA-model seems to be somewhat similar to a stroke or
trauma observed in patients in which besides the primarily
degenerated core region with rapidly dying cells there is a
wide penumbra zone where cells can be salvaged within
several hours. Effectiveness of neuroprotection after
delayed treatment, found in our studies together with the
ﬁndings that EMQMCM may be protective also after sys-
temic injection (Makarewicz et al. 2006; Szydlowska et al.
2007) may inspire hope that such compound might
diminish the penumbra.
Our present in vitro results indicate that the neuropro-
tective action of EMQMCM can be at least partially
attributed to the reduction of apoptosis, as it decreased the
KA-induced caspase-3 activation. The caspase-3 activation
is a good marker of apoptosis used for quantitative analy-
sis. Schedule in this experiment was based on our previous
studies concerning the neuroprotective action of the
mGluR5 antagonist MTEP (Domin et al. 2006). Our
present ﬁnding is quite a new one because till now there
have been a few papers only concerning the inﬂuence of
mGluR1 ligands on apoptosis (and no studies concerning
EMQMCM). Based on the spinal cord neuropathic model
Siniscalco et al. (2008) found an antiapoptotic effect of the
mGluR1 antagonist JNJ16259685 in the spinal dorsal horn
using TUNEL and immunohistochemical methods. In
contrast, Allen et al. (2000), using the in vitro ischemic
models, showed that mGluR1 activation was connected
mainly with necrotic cell death and the inhibition of these
receptors attenuated necrosis. Our results demonstrate a
strong antiapoptotic effect of EMQMCM. The KA-induced
Fig. 5 Effect of EMQMCM (100 lM) on extracellular GLU (a) and
GABA (b) level in the rat hippocampus. EMQMCM administration is
indicated with an arrow, while horizontal bar shows duration of
treatment. Data are means ± SEM (n = 4–10). Repeated measures
ANOVA and Tukey’s post hoc test. *P\0.05, **P\0.01 in
comparison with control
Fig. 6 Effect of EMQMCM (100 lM) and kainic acid (KA 50 lM)
on extracellular GLU (a) and GABA (b) level in the rat hippocampus.
EMQMCM and KA administration is indicated with an arrow, while
horizontal bar shows duration of treatment. Data are means ± SEM
(n = 4–10). Repeated measures ANOVA and Tukey’s post hoc test.
*P\0.05, **P\0.01 in comparison with control; ^P\0.05,
^^P\0.01 in comparison to group treated with KA
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123increase in caspase-3 activity was entirely blocked by the
compound in all concentrations studied (0.1–100 lM). The
effect of EMQMCM on the apoptosis was evidenced not
only by means of caspase-3 measurements but also by
microscopic observations of cultures stained by Hoechst
method in which density of apoptotic bodies clearly
decreased after the drug addition. The microscopic obser-
vations were not quantiﬁed but were an additional illus-
tration visualizing the actual apoptosis corresponding with
quantitative results obtained by caspase-3 activity
measurements.
To study the mechanism of neuroprotective action of
EMQMCM, the microdialysis method was used. We
investigated the effects of EMQMCM on glutamate and
GABA release in the hippocampus of freely moving rats.
The results show a strong enhancement of GABA release
after the drug treatment while the level of extracellular
glutamate was decreased. Analysis of the time courses of
changes in GABA and glutamate level in the perfusates
suggests that the primary effect of EMQMCM involves the
action on GABA as its level increases immediately after
the drug application and peaks after 60 min, while the
decreasing effect on glutamate seems to be secondary,
starting at 60 min and reaching signiﬁcance at 90 and
120 min after application.
KA induced a tremendous increase in the glutamate
release shortly after the toxin application, and a weaker
increase in the GABA level which appeared later. KA in
microdialysis was used in lower concentration than in in
vitro experiments. The preliminary studies indicated that
50-lM KA did not induce seizures while it markedly
affected glutamate release. EMQMCM co-administered
with KA strongly enhanced the KA-induced GABA
release; the values were about twice higher than KA alone.
At the same time EMQMCM prevented the KA-stimulated
glutamate release. A signiﬁcant regulating effect of
EMQMCM on GABAergic and glutamatergic function
may be connected with anatomical distribution of its target
receptors. It has been found that mGlu1 receptors are
extensively expressed throughout the brain with medium to
high levels in some cortical and hippocampal regions
(Spooren et al. 2003) and are localized mainly postsynap-
tically but also presynaptically (Ferraguti et al. 2008). In
the hippocampus, mGlu1 receptors are expressed mainly in
GABA interneurons but also in principal glutamatergic
neurons (Shigemoto et al. 1997; Ferraguti et al. 2008), and
a modulation of GABAergic transmission has been postu-
lated (Speed and Dobrunz 2008). Presynaptic mGlu1
autoreceptors on glutamatergic terminals were found in the
mouse cerebral cortex (Musante et al. 2008).
There are no studies yet on the inﬂuence of EMQMCM
on GABA and glutamate output in brain structures, but the
results obtained with other mGluR1 antagonists are
generally in line with our ﬁndings. Pellegrini-Giampietro
et al. (1999) using a microdialysis study in freely moving
gerbils showed a highly signiﬁcant increase in the con-
centration of GABA in hippocampal dialysates, but no
changes in glutamate, after the mGluR1 antagonist, AIDA
treatment. The reason of the discrepancy concerning glu-
tamate may arise from the fact that the cited authors used a
much shorter time of experiment than we did; they per-
fused the hippocampus with AIDA for 9 min only and
collected the perfusate immediately after the treatment
whereas the effect on glutamate release appeared in our
experiments much later, 90 and 120 min after the perfusion
onset and was probably a secondary effect. Moreover, these
authors studied the effect of AIDA alone but did not
examine whether it changed the effects of excitatory com-
pounds on amino acids release, so our results provide a much
more complex information. The longer time of experiment
was used by Cozzi et al. (2002), namely the antagonists,
AIDA and CBPG, perfused for 60 min, protected pyramidal
CA1 neurons in gerbils’ hippocampus subjected to global
ischemia and induced substantial increase in GABA release
and minor elevation of glutamate output. Another research
group, Battaglia et al. (2001), using microdialysis in the rat
striatum, studied the effect of two mGluR1 antagonists:
competitive LY367385 and uncompetitive CPCCOEt during
a 20-min perfusion on NMDA-induced release of glutamate
and found no effect or even increase in the level of glutamate
in the striatal perfusate. At the same time, GABA release was
substantially enhanced. Different results were obtained dur-
ing the microdialysis of rat periaqueductal gray where
CPCCOEt (a selective mGluR1 antagonist) given alone did
not change the GABA or glutamate release but antagonized
the release of these amino acids induced by DHPG (a group I
mGluR agonist) (de Novellis et al. 2003). Therefore, all those
ﬁndings show that a selective blockade of mGlu1 receptors
produces the enhancement in GABAergic transmission
which is in line with our present results. Moreover, the
results of Cozzi et al. (2002) suggested an important role of
GABA activation in the neuroprotective effects of studied
mGluR1 antagonists, as the protection was reduced by
GABA receptor antagonists and was mimicked by GABA
and GABA receptor agonists.
In conclusion, the results obtained in this study demon-
strated signiﬁcant neuroprotective effects of the mGluR1
antagonist EMQMCM in excitotoxicity. Neuroprotection
evoked by EMQMCM may arise from an enhancement of
inhibitory GABAergic transmission and a suppression of
excitatory glutamatergic transmission. It seems to be impor-
tant that the compound reveals its protective activity even
when the treatment is delayed by up to 3–6 h after the intox-
icationonset,whichmaygiveusahopeforfuturetherapeutic
use of similar compounds in patients to whom the neuropro-
tective treatment can be applied a few hours after damage.
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